Niels Riedemann

Company: Inflarx

Job title: Chief Executive Officer

Seminars:

Phase 3 Development of First-in-Class C5a Inhibitor Vilobelimab: Transforming Treatment for Pyoderma Gangrenosum 3:15 pm

Understand C5a inhibition how demonstrates a novel mechanism for targeting neutrophil-driven inflammation in PG  Examine Phase 1 and 2a clinical data showcasing safety profile and biological proof of concept across multiple indications  Discover the strategic approach to Phase 3 trial design that builds on demonstrated efficacy while addressing rare disease challengesRead more

day: Day One

Panel Discussion: Strategic Considerations for Clinical Success in Hidradenitis Suppurativa 9:30 am

Explore how leading developers are balancing the need for regulatory-aligned endpoints with endpoints that demonstrate value to payers and patients  Debate strategies for designing more efficient trials through novel endpoint combinations and timing of assessments to accelerate development timelines  Understand different approaches to generating compelling evidence packages that support both regulatory approval and market access…Read more

day: Day Two